Author

Philip A. Gerrard

Observed names: P A Gerrard, P. A. Gerrard, P.A. Gerrard, Philip Gerrard

Institution: Aptuit (Italy)

Observed institutions: University of Bradford, GlaxoSmithKline (Italy), Aptuit (Italy), Evotec (United States)

OpenAlex ID: A5108206421

The effects of ondansetron, a 5-HT3 receptor antagonist, on cognition in rodents and primates

1990 · J.M. Barnes, B. Costall, et al. · Pharmacology Biochemistry and Behavior · 195

Zacopride: anxiolytic profile in rodent and primate models of anxiety

1988 · B Costall, A M Domeney, et al. · Journal of Pharmacy and Pharmacology · 167

Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist

1991 · R.J. Eden, B. Costall, et al. · Pharmacology Biochemistry and Behavior · 135

Alterations in neuropeptide Y and Y1 receptor mRNA expression in brains from an animal model of depression: region specific adaptation after fluoxetine treatment

1998 · Laura Caberlotto, Kjell Fuxe, et al. · Molecular Brain Research · 109

Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania

2004 · Roberto Arban, Gabriella Maraia, et al. · Behavioural Brain Research · 92

PRECLINICAL STUDY: Correlation between serum ghrelin levels and cocaine‐seeking behaviour triggered by cocaine‐associated conditioned stimuli in rats

2007 · Michela Tessari, Antonio Catalano, et al. · Addiction Biology · 86

The effect of ondansetron on cognitive performance in the marmoset

1991 · A.M. Domeney, B. Costall, et al. · Pharmacology Biochemistry and Behavior · 82

Anxiolytic-like effect of the selective Neuropeptide Y Y2 receptor antagonist BIIE0246 in the elevated plus-maze

2006 · Fabrizio Bacchi, Aleksander A. Mathé, et al. · Peptides · 79

Effects of captopril and SQ29,852 on anxiety-related behaviours in rodent and marmoset

1990 · B. Costall, A.M. Domeney, et al. · Pharmacology Biochemistry and Behavior · 65

Effects of antidepressant drugs and GR 205171, an neurokinin-1 (NK1) receptor antagonist, on the response in the forced swim test and on monoamine extracellular levels in the frontal cortex of the mouse

2003 · Alessandro Zocchi, Giorgia Varnier, et al. · Neuroscience Letters · 63

Ondansetron and arecoline prevent scopolamine-induced cognitive deficits in the marmoset

1992 · G.J. Carey, B. Costall, et al. · Pharmacology Biochemistry and Behavior · 61

Discovery Process and Pharmacological Characterization of 2-(S)-(4-Fluoro-2-methylphenyl)piperazine-1-carboxylic Acid [1-(R)-(3,5-Bis-trifluoromethylphenyl)ethyl]methylamide (Vestipitant) as a Potent, Selective, and Orally Active NK1 Receptor Antagonist

2009 · Romano Di Fabio, Cristiana Griffante, et al. · Journal of Medicinal Chemistry · 54

Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders

2011 · Romano Di Fabio, Annalisa Pellacani, et al. · Bioorganic & Medicinal Chemistry Letters · 53

Anxiolytic profile of ropinirole in the rat, mouse and common marmoset

2000 · D.C. Rogers, B. Costall, et al. · Psychopharmacology · 51

Discovery and Biological Characterization of (2R,4S)-1′-Acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4′-bipiperidine-1-carboxamide as a New Potent and Selective Neurokinin 1 (NK1) Receptor Antagonist Clinical Candidate

2011 · Romano Di Fabio, Giuseppe Alvaro, et al. · Journal of Medicinal Chemistry · 36

A novel process driving Alzheimer's disease validated in a mouse model: Therapeutic potential

2022 · Susan A. Greenfield, Gregory M. Cole, et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions · 27

PDF

Transient forebrain over-expression of CRF induces plasma corticosterone and mild behavioural changes in adult conditional CRF transgenic mice

2009 · Elena Vicentini, Roberto Arban, et al. · Pharmacology Biochemistry and Behavior · 27

The effects of umespirone as a potential anxiolytic and antipsychotic agent

1991 · N.M. Barnes, B. Costall, et al. · Pharmacology Biochemistry and Behavior · 26

Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate

2013 · Romano Di Fabio, Giuseppe Alvaro, et al. · Bioorganic & Medicinal Chemistry · 25

Receptor distribution studies

2017 · Renzo Carletti, Stefano Tacconi, et al. · Current Opinion in Pharmacology · 10

The NK 1 receptor antagonist aprepitant attenuates NK 1 agonist‐induced scratching behaviour in the gerbil after intra‐dermal, topical or oral administration

2015 · Vivian J. A. Costantini, Mauro Corsi, et al. · Experimental Dermatology · 8

Vasopressin 1A (V1A) Receptor Antagonists Reduce Anxiety in Marmosets

2020 · Tanya Wallace, Tod Steinfeld, et al. · Biological Psychiatry · 4

In vitro hippocampal slices and in vivo video–tEEG model in rat to assess convulsion/seizure risk of novel compounds

2015 · Nicola Fasdelli, Chiara Rostello, et al. · Journal of Pharmacological and Toxicological Methods

Inclusion of neurobehavioural and respiratory safety pharmacology endpoints in the four-week rat general toxicology studies: A CRO perspective

2014 · Nicola Fasdelli, Maria Pilla, et al. · Journal of Pharmacological and Toxicological Methods

Validation of FOB in two rat strains: Crl:CD(SD) vs Crl:WI(Han) rats

2014 · Maria Pilla, Alessia Guidi, et al. · Journal of Pharmacological and Toxicological Methods

Works count: 36

Citation count: 1,455

H-index: 19

I10-index: 20